Fresenius Medical Care Grows Variety of U.S. Sufferers Utilizing Firm’s Dwelling Hemodialysis Machines, Launches NxStage ® Versi ®HD with GuideMe Software program

• Fresenius Medical Care (NYSE:) achieves progress milestone of greater than 14,000 U.S.-based sufferers utilizing the Firm’s NxStage programs to carry out Dwelling Hemodialysis remedy
• This progress has generated larger adoption from a spread of dialysis suppliers and delivers on the corporate’s dedication to develop entry to and use of dwelling dialysis remedy
• The most recent NxStage ^® Versi ^®HD with GuideMe Software program dwelling dialysis machine is designed to simplify therapy, enhance ease of studying, and enhance consumer expertise

WALTHAM, Mass., Sept. 4, 2024 /PRNewswire/ — Fresenius Medical Care (FME), a world chief in kidney care, has achieved a progress milestone of greater than 14,000 U.S.-based sufferers utilizing the Firm’s NxStage programs to carry out Dwelling Hemodialysis (HHD) remedy by each Fresenius Kidney Care clinics and different suppliers. The corporate has in parallel launched the latest model of its dwelling dialysis machine, the NxStage ^® Versi ^®HD with GuideMe Software program, that includes enhancements designed to simplify therapy, enhance ease of studying, and enhance consumer expertise. These achievements spotlight the efficacy and reliability of the NxStage system in delivering secure, high-quality care to sufferers within the consolation of their houses.

Between January and April 2024, the variety of new HHD sufferers beginning therapy with NxStage in the USA grew by 18% in comparison with the identical interval in 2023. For instance, April noticed 927 new sufferers initiating HHD remedy within the U.S.

“We’re proud to announce these achievements in our Dwelling Therapies division,” stated Joseph Turk, Govt Vice President and World Head of Dwelling Therapies at Fresenius Medical Care. “These accomplishments underscore our relentless dedication to steady improvements that allow us to enhance the lives of sufferers in search of the security, comfort, and adaptability of dwelling dialysis.”

Because the FDA clearance in 2023, the latest NxStage HHD System, Versi ^®HD with GuideMe Software program, has garnered important curiosity in the USA. Massive, mid-sized, and a number of other impartial dialysis suppliers are shifting ahead with the adoption of Versi ^®HD with GuideMe Software program.

Versi ®HD with GuideMe Software program’s superior know-how is designed to simplify HHD therapy and enhance ease of studying, talent retention, and consumer expertise for sufferers and care companions. The machine’s pictorial-based steering was designed to satisfy numerous affected person wants all through the setup, therapy and troubleshooting, whereas bettering coaching time and talent retention. It supplies graphical walk-through steering that goals to boost ease of use and confidence for each sufferers and nurses. The interface is designed to accommodate all kinds of studying kinds and enhance talent retention from preliminary coaching, whereas static image directions permit sufferers to linger and research any step at their very own tempo.

“The affected person coaching on Versi ^®HD with GuideMe-Software program at our clinic catch on rapidly and really feel snug by the second week of coaching. Even higher, they’re able to full their coaching seven to 10 days sooner,” stated Sandra Flores, Dwelling Therapies Registered Nurse in North Central Oklahoma Metropolis.

At present, NxStage Versi ®HD  with GuideMe Software program is being totally launched within the U.S. with deliberate world rollouts over the approaching years. For extra details about Fresenius Medical Care’s Dwelling Therapies, please go to https://www.nxstage.com/hcp/merchandise/nxstage-versihd-with-guideme-software/

© 2024 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle emblem, NxStage, and Versi are logos of Fresenius Medical Care Holdings, Inc. or its affiliated corporations. All different logos are the property of their respective house owners.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s main supplier of services and products for people with renal illnesses of which round 4.1 million sufferers worldwide often bear dialysis therapy. Via its community of three,757 dialysis clinics, Fresenius Medical Care supplies dialysis remedies for approx. 311,000 sufferers across the globe. Fresenius Medical Care can be the main supplier of dialysis merchandise equivalent to dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Inventory Change (FME) and on the New York Inventory Change (FMS).

For extra info go to the Firm’s web site at  www.freseniusmedicalcare.com.

Disclaimer:
This launch accommodates forward-looking statements which are topic to numerous dangers and uncertainties. Precise outcomes may differ materially from these described in these forward-looking statements as a consequence of varied components, together with, however not restricted to, modifications in enterprise, financial and aggressive circumstances, authorized modifications, regulatory approvals, impacts associated to the COVID-19 pandemic outcomes of medical research, international alternate charge fluctuations, uncertainties in litigation or investigative proceedings, and the supply of financing. These and different dangers and uncertainties are detailed in Fresenius Medical Care’s reviews filed with the U.S. Securities and Change Fee. Fresenius Medical Care doesn’t undertake any duty to replace the forward-looking statements on this launch.

Media contact
Emanuela Cariolagian
T +1 213 706 0051
[email protected]

Christine PetersT +49 160 60 66 770
[email protected]

Contact for analysts and traders
Dr. Dominik HegerT +49 6172 609 2601
[email protected]